Optiray (Ioversol)

Ioversol, the active ingredient in Optiray, is an iodinated contrast media presented as a solution for injection for intra‑arterial and intravenous use. It enhances radiodensity during diagnostic imaging procedures, allowing clearer visualization of vascular and tissue structures in patients undergoing angiography, computed tomography, urography, venography, or cardiac catheterization.

GNH USA supplies Optiray as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Optiray, an iodinated contrast media, is used in diagnostic imaging procedures that require enhanced X‑ray attenuation.

- Angiography: provides enhanced vascular visualization for diagnostic and interventional procedures. - Computed tomography (CT) imaging: improves tissue contrast to aid detection of lesions and anatomical detail. - Urography: highlights urinary tract structures for accurate assessment of kidneys, ureters and bladder. - Venography: delineates venous anatomy to evaluate thrombosis or vascular malformations. - Cardiac catheterization: enhances coronary and cardiac chamber imaging during interventional studies.

Adverse reactions may occur following administration of iodinated contrast media.

Common Side Effects: - Warmth or flushing sensation at the injection site. - Transient metallic taste in the mouth. - Mild nausea or vomiting. - Headache or mild dizziness. - Mild urticaria or itching. - Injection site discomfort or bruising.

Serious or Rare Side Effects: - Anaphylactoid or severe allergic reaction (anaphylaxis). - Acute kidney injury or worsening of pre‑existing renal impairment. - Severe hypotension or cardiovascular collapse. - Pulmonary edema or respiratory distress. - Seizures or neurologic disturbances. - Cardiac arrhythmias or myocardial ischemia.

Prior to administration, clinicians should evaluate patient‑specific risk factors and follow safe handling practices.

- Assess renal function: check serum creatinine and eGFR before use. - Review allergy history: identify prior reactions to iodinated contrast or iodine‑containing products. - Use the lowest effective dose: tailor volume to the imaging study and patient size. - Monitor vital signs: observe blood pressure, heart rate and oxygen saturation during and after injection. - Avoid in patients with known iodine hypersensitivity: consider alternative imaging methods. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Ioversol may interact with other agents that affect renal function or iodine metabolism.

Major Interactions (Avoid): - Concurrent use of other iodinated contrast agents within 24 hours. - Nephrotoxic drugs such as aminoglycosides, high‑dose NSAIDs, or amphotericin B. - Radioactive iodine therapy or thyroid hormone suppression regimens.

Moderate Interactions (Monitor Closely): - Metformin in patients with impaired renal function: hold metformin before and after contrast exposure. - Diuretics and ACE inhibitors: monitor fluid balance and renal parameters. - Beta‑blockers and calcium channel blockers: observe for exaggerated hemodynamic responses.